FDA ODAC Votes in Support of DARZALEX FASPRO for High-Risk Smoldering Myeloma Read more about FDA ODAC Votes in Support of DARZALEX FASPRO for High-Risk Smoldering MyelomaAdd new comment
May 2025 – Myeloma News from the Journals Read more about May 2025 – Myeloma News from the JournalsAdd new comment
2025 Myeloma Action Month Celebrates #MyelomaMilestones Read more about 2025 Myeloma Action Month Celebrates #MyelomaMilestonesAdd new comment
The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer Read more about The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’DwyerAdd new comment
European Commission Grants Conditional Marketing Approval of Lynozyfi (linvoseltamab) for Relapsed/Refractory Multiple Myeloma Read more about European Commission Grants Conditional Marketing Approval of Lynozyfi (linvoseltamab) for Relapsed/Refractory Multiple MyelomaAdd new comment
April 2025 – Myeloma News from the Journals Read more about April 2025 – Myeloma News from the JournalsAdd new comment
UK MHRA Approves GSK’s BLENREP® in Combination with BVd and BPd for the Treatment of Adult RRMM Patients Read more about UK MHRA Approves GSK’s BLENREP® in Combination with BVd and BPd for the Treatment of Adult RRMM PatientsAdd new comment
The International Myeloma Foundation Congratulates Medical Student Scholar Tyra Grischke and Her Mentor Dr. Ben Derman for Their Blood Cancer Journal Publication Read more about The International Myeloma Foundation Congratulates Medical Student Scholar Tyra Grischke and Her Mentor Dr. Ben Derman for Their Blood Cancer Journal PublicationAdd new comment
Over 53 Million Myeloma Milestones Shared During 2025 Myeloma Action Month Read more about Over 53 Million Myeloma Milestones Shared During 2025 Myeloma Action Month Add new comment
